The future of combination immunotherapy in oesophageal adenocarcinoma

Front Immunol. 2023 Jul 14:14:1217132. doi: 10.3389/fimmu.2023.1217132. eCollection 2023.

Authors

Maria Davern¹, Noel E Donlon^{2

3}

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
² Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.
³ Department of Upper GI Surgery, Beaumont Hospital, Dublin, Ireland.

No abstract available

Keywords: CTLA-4; PD-1; TIGIT; chemoradiotherapy; chemotherapy; immunotherapy; neoadjuvant; oesophageal.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma* / therapy
Esophageal Neoplasms* / pathology
Esophageal Neoplasms* / therapy
Humans
Immunotherapy

Supplementary concepts

Adenocarcinoma Of Esophagus

Grants and funding

Trinity Translational Medicine Institute Building Engagements in Health Research Pilot Award.